ConcertAl's TeraRecon Launches ThreeNew Care Suites, Life SciencesPlatform, and Strategic Partnerships at#ECR24
by TeraRecon, on Feb 26, 2024 10:47:34 AM
New Clinical Al care suites for Cardiology, Pulmonology, and Neurology; First-in-Class multi-modal predictive and Gen Al platform for
research and clinical modeldevelopment
CAMBRIDGE, Mass., Feb.26,2024/PRNewswire/-- ConcertAl's TeraRecon, the #lKLAS-ranked advanced visualization and Al Clinical SaaS
solution, has announcedthat European healthcare providers now have access to its cardiology, pulmonology,and neurology suites. In
addition, the company initiated new partnerships withseveral leading CE-marked Al software developers, including Gleamer, LucidaMedical,
and Perspectum. TeraRecon now provides a leading unified solution forclinical Al algorithms in Europe across radiology, neurology,
oncology, pulmonology,and cardiology.
TeraRecon's Al Partnerships for the EU market now include:
GLEAMER brings their groundbreaking BoneView solution, CE marked and FDA-cleared, utilizes Al for bone fracture identification. Meanwhile, ChestView (CE) aidsin the detection of pulmonary nodules.
Lucida Medical Al-machine learning software, Pirm, is designed to helpradiologists identify prostate cancer lesions from MRl.
Perspectum's LiverMultiscan and MRCp+ provide clinicians with quantitativemetrics to assess liver tissue characteristics to aid in the
detection of chronic livedisease and helps facilitate visualization and quantitative assessment of thebiliary tree and pancreatic duct.
Schedule a demo at ECR 2024 to see both TeraRecon and partner solutions live. Youcan also reserve time to see the new features of our
flagship Intuition product.including clinical and interventional preoperative cardiovascular planning workflows.cardiac CT and MR workflows,
and many more enhancements that integrateseamlessly within the clinicians' workflow to enhance diagnostics, care delivery andtracking
over time.
Please join us and Cercare Medical for a joint networking event in Expo Hall Xl, atbooths Al05 & Al06 on Friday, March ist from 3:30 - 5:00
PM. You'll be able to meetfellow radiologists, developers, subject matter experts, and representatives that cananswer all your questions
around Clinical lmaging Al in general across radiology,neurology, cardiology, vascular surgery, and oncology.
Outside the show floor, TeraRecon and Perspectum will present an Al Lightning Talk,titled Integrating Al in Clinical Care on Friday March 1st
@ 12:50PM.
Another exciting launch at ECR is an integrated multi-modal data Al Software-as-a-Service platform designed for oncology biomedical
translational and clinicalresearch, Al model development, multi-modal data management. This first-in-classplatform seamlessly integrates
Intuition advanced visualization, TeraRecon clinical Alimaging solutions, digital pathology, genomics, and electronic medical recordderived
clinical data.
"Over the past two years, we have focused on the importance of multi-modal data Almodel development, validation, stability monitoring,
and deployment for insights, aspart of clinical trials, and ultimately, clinical care," said Jeff Elton, PhD CEO ofConcertAl."Multi-modal data
enable causal inferences and elimination ofconfounders for interpretations and predictions. Enabling this required rethinkingthe tools
available to biomedical researchers, while leveraging the power ofGenerative Al. As a ground-up new approach that allows multi-modal
datamanagement, Al model development validation, model management, and modelrelease we can bring the power of deep and wide data
at scale, our large researchnetwork, and latest predictive Al and Gen Al together for the broadest researchcommunity use."
About ConcertAl: ConcertAl is the leader in Predictive and Generative Al SaaS andReal-world Data research solutions and healthcare and life
sciences. Our mission isto accelerate insights and outcomes for patients through research-ready data,CARA™ Al technologies, and scientific
expertise in partnership with the leadingbiomedical innovators, health care providers, and medical societies. Serving over1,900 clinical sites
and 45 biomedical innovators ConcertAl companies and solutionsare "Best in KLAS" and awarded the 2020, 2021, and 2022 KLAS
recognition.CancerLinQ® is an Initiative of ConcertAl, providing oncology providers AsCoaligned automated QOPl quality solutions and
SmartLinQ analytic services.Headquartered in Cambridge, MA, ConcertAl has offices in Philadelphia, Frankfurt.Raleigh-Durham, and Tokyo.
For more information, visit us at www.concertai.com
About TeraRecon: Serving ~1,900 clinical sites globally, TeraRecon, a ConcertAlcompany, is a Best in KLAS solution provider for Al
empowered radiology, oncology.cardiology, neurology, and vascular surgery. Awarded the KLAS Category Leader forAdvanced Visualization,
TeraRecon solutions are independent of any onemanufacturer's imaging equipment or PAcS system, allowing a single, unified, andsimplified
clinical workflow that can improve efficiencies and deliver actionablephysician-guided insights. For more information, visit us at
www.terarecon.com.